*THERE IS A TRACE AMOUNT OF NATURALLY OCCURRING THC DERIVED FROM INDUSTRIAL HEMP IN OUR CBD HEMP OIL. FOR THIS REASON IT IS POSSIBLE TO TEST POSITIVE FOR A THC DRUG ANALYSIS. Although psycho-actively the THC level is a negligible amount, it could still potentially cause a failed drug test.*
ABOUT OUR CBD HEMP OIL:
MAIN INGREDIENT: cannabidiol (CBD) extract
The main ingredient in our CBD Hemp oil is a cannabidiol (CBD) extract derived from the industrial cultivation of Cannabis sativa. Industrial hemp is ideal for cannabidiol (CBD) extractions as it is naturally high in CBD and low in THC, making it superior to most high-THC strains as far as CBD content is concerned.
The hemp we use is grown on family farms in countries where it is legal to do so, and is done under the regulation of the governing bodies in those countries. Hemp, because of it's innate ability to thrive so easily, doesn't require pesticides, fertilizers, or herbicides in it's cultivation, and barely needs water compared to standard commercial farming. Our hemp is NON-GMO and is grown under the same methods and standards of organic farming, but at this time there is no actual legal procedure for the organic certification of hemp cultivation. We're expecting the process for organic certification of hemp to be available within the next year, and we will officially certify ours as soon as we can.
Our raw hemp is then imported legally into the U.S. following FDA regulations, where it is extracted through a CO2 extraction and analyzed at a certified GMP (Good Manufacturing Practice) facility. To determine the purity and potency of every batch each extraction is analyzed through a High Pressure Liquid Chromatography (HPLC) test for aerobic organisms, yeast, fungus, E. coli, coliforms and heavy toxic metals, and is also analyzed for the potency and standardization of it's natural constituents. The HPLC test is commonly regarded as the most precise and efficient way to analyze phyto-chemicals and plant extracts. With this analysis performed we can weigh the CBD extract for making our blends knowing that the cannabidiol content is pure and consistent throughout every batch we make.
A specific amount of cannabidiol (in milligrams) is weighed and distributed accordingly into each bottle we make.
Industrial hemp products, like our CBD extract, are considered a dietary and nutritional supplement according to the FDA and are legal to sell, possess and consume in the United States.
Hemp seed oil- cold pressed from hemp seeds. This is also from an industrial hemp variety of Cannabis sativa which doesn't require herbicides, pesticides, and fertilizers. Hemp seed oil is considered very nutritious, but the main purpose for it being in our blend is to have a base oil to emulsify the CBD extract into. Because the CBD extract is a thick tar-like substance that is messy to handle and work with, it is much easier to package and consume when mixed into a blend like we have done. And we figured if we're going to emulsify the cannabidiol extract into a base oil, what more appropriate oil could there be than to use hemp seed oil for this purpose.
Vegetable glycerin- Certified organic palm glycerin. Just a little is used to cut the bitterness of the CBD extract.
Water- Eldorado Springs water from
Colorado, U.S. It's the best local water we have in this area of Colorado.
"Cannabidiol (CBD) is one of at least 85 cannabinoids found in cannabis. It is a major constituent of the plant, second to tetrahydrocannabinol (THC), and represents up to 40% in its extracts. Compared with THC, cannabidiol is not psychoactive in healthy individuals, and is considered to have a wider scope of medical applications than THC, including to epilepsy, multiple sclerosis spasms, anxiety disorders, bipolar disorder, schizophrenia, nausea, convulsion and inflammation, as well as inhibiting cancer cell growth. There is some preclinical evidence from studies in animals that suggests CBD may modestly reduce the clearance of THC from the body by interfering with its metabolism. Cannabidiol has displayed sedative effects in animal tests. Other research indicates that CBD increases alertness. CBD has been shown to reduce growth of aggressive human breast cancer cells in vitro, and to reduce their invasiveness."
CBD has been shown to inhibit meticillin-resistant staphylococcus aureus (MRSA) in vitro. CBD, along with the cannabis terpenoid pinene, are effective against MRSA, and may exhibit antiseptic effects against Propionibacterium acnes, the key pathogen in acne. CBD absorbed transcutaneously may also attenuate the increased sebum production at the root of acne."
A 2010 study found that strains of cannabis containing higher concentrations of cannabidiol did not produce short-term memory impairment vs. strains with similar concentrations of THC, but lower concentrations of CBD. The researchers attributed this attenuation of memory effects to CBD's role as a CB1 antagonist. CBD also appears to protect against 'binge' alcohol induced neurodegeneration.
There have been numerous case reports and one small clinical trial documenting the ability of CBD to reduce seizure frequency in epilepsy including in treatment-refractory cases of childhood epilepsy syndromes (for example dravet syndrome).
Cannabidiol's strong antioxidant properties have been shown to play a role in the compound's neuroprotective and anti-ischemic effects.
Cannabidiol has proven effective in treating an often drug-induced set of neurological movement disorders known as dystonia. In one study, five out of five participants showed noted improvement in their dystonic symptoms by 20-50%."
"A 2008 study published in the British Journal of Psychiatry showed significant differences in the Oxford-Liverpool Inventory of Feelings and Experiences scores between three groups: the first consisted of non-cannabis users, the second consisted of users with THC detected, and the third consisted of users with both THC and CBD detected. The THC-only group scored significantly higher for unusual experiences than the THC-and-CBD group, whereas the THC-and-CBD group had significantly lower introvertive anhedonia scores than the THC-only group and the non-cannabis user group. This research indicates that CBD acts as an anti-psychotic and may counteract the potential psychotomimetic effects of THC on individuals with latent schizophrenia.
Recent studies have shown cannabidiol to be as effective as atypical antipsychotics in treating schizophrenia. Studies have shown CBD may reduce schizophrenic symptoms due to its apparent ability to stabilize disrupted or disabled NMDA receptor pathways in the brain, which are shared and sometimes contested by norepinephrine and GABA. Leweke et al. performed a double blind, 4 week, explorative controlled clinical trial to compare the effects of purified cannabidiol and the atypical antipsychotic amisulpride on improving the symptoms of schizophrenia in 42 patients with acute paranoid schizophrenia. Both treatments were associated with a significant decrease of psychotic symptoms after 2 and 4 weeks as assessed by Brief Psychiatric Rating Scale and Positive and Negative Syndrome Scale. While there was no statistical difference between the two treatment groups, cannabidiol induced significantly fewer side effects (extrapyramidal symptoms, increase in prolactin, weight gain) when compared to amisulpride.
Studies have shown cannabidiol decreases activity of the limbic system and decreases social isolation induced by THC. Cannabidiol has also been shown to reduce anxiety in social anxiety disorder. Although in rats chronic cannabidiol administration was recently found to produce anxiogenic-like effects, hence indicating that, prolonged treatment with cannabidiol might incite anxiogenic effects. Cannabidiol has demonstrated antidepressant-like effects in animal models of depression."
In November 2007, researchers at the California Pacific Medical Center reported that CBD shows promise for controlling the spread of metastatic breast cancer. In vitro CBD down-regulates, or "turns off", the activity of ID1, the gene responsible for tumor metastasis in breast and other types of cancers, including the particularly aggressivetriple negative breast cancer. The researchers in September 2012 said they hope to start human trials soon.
Cannabidiol has been shown to inhibit cancer cell growth with low potency in non-cancer cells. Although the inhibitory mechanism is not yet fully understood, Ligresti et al. suggest that "cannabidiol exerts its effects on these cells through a combination of mechanisms that include either direct or indirect activation of CB2 and TRPV1 receptors, and induction of oxidative stress, all contributing to induce apoptosis."
Non-psychoactive cannabinoids, including cannabidiol (CBD) and other more pronounced CB2 agonists such as cannabinol (CBN, an immunosuppressant), are now seen as promising targets for anti-tumor drugs since they experimentally reduce the size of in-vivo xenografts, for example gliomas. Combinations of submaximal THC doses and CBD have both been successfully applied to greatly increasein-vitro efficacy of temozolomide in glioblastoma multiforme cell lines. CBD likely exerts its effects through the induction of apoptosis by Reactive oxygen species. Non-psychoactive cannabinoids can be administered at much higher doses without the well-known side effects that are sometimes associated with the drop-out rate in trials involving psychoactive cannabinoids.
A team of researchers from the University of California at Irvine proposed in February 2013 that CBD's anti-malignant effect by way of apoptosis may be due to its potential action on "mutant p53 proteins in cancer cells," due to cannabidiol's chemo-physical similarity to stictic acid, a promising anti-cancer compound found in some species of lichens that acts on the aforementioned proteins. The University biologists, chemists and computer scientists "identified an elusive pocket on the surface of the p53 protein that can be targeted by cancer-fighting drugs"."
Dravet syndrome is a rare form of epilepsy that is resistant to most anti-epileptic medications. In the October 2013 edition of The Nation, CBD was touted as the "single compound in cannabis [that] may revolutionize modern medicine". The article went on to say that "nothing else is able to help treatment-resistant epileptic children with Dravet syndrome and related disorders."
The 2013 CNN documentary Weed: Dr. Sanjay Gupta Reports featured a medical marijuana strain containing virtually no THC and a high percentage of CBD (0.76% THC and 17.61% CBD) that was being used successfully to treat a 5-year-old Colorado medical marijuana patient who suffers with Dravet syndrome. In 2010, a Modesto, California father reported that he had experienced success treating his son's case of Dravet Syndrome with a CBD-rich cannabis tincture. His 5-year-old son went from a daily dose of 22 pharmaceutical pills down to four, began eating solid food, and experiencing fewer and less intense seizures since beginning treatment with CBD. Before using the tincture, the boy experienced seizures "24 hours a day lasting an hour and a half", but since the first day the high-CBD tincture was administered, he has been seizure free." -Wikipedia